Monoclonal Antibody to Regenerating Islet Derived Protein 1 Alpha (REG1a)
| Code | Size | Price |
|---|
| MAB760Hu22-20ul | 20ul | £87.00 |
Quantity:
| MAB760Hu22-100ul | 100ul | £162.00 |
Quantity:
| MAB760Hu22-200ul | 200ul | £219.00 |
Quantity:
| MAB760Hu22-1ml | 1ml | £502.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
REG; PSP; ICRF; PSPS1; PTP; Islet cells regeneration factor; Islet of Langerhans regenerating protein; Lithostathine 1 Alpha; Pancreatic Stone Protein; Pancreatic Thread Protein
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Regenerating Islet Derived Protein 1 Alpha
Potency (Clone Number):
C4
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.2-2ug/mL;1:500-5000
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Regenerating Islet Derived Protein 1 Alpha (REG1a) | RPB760Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||